Trials / Recruiting
RecruitingNCT06386302
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
A Multicenter, Randomized, Controlled Clinical Trial of Chidamide Combined With Venetoclax and Azacitidine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Not Suitable for Intensive Chemotherapy
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 184 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide | 30 mg/d orally twice-weekly |
| DRUG | Venetoclax | 100 mg d1 200 mg d 2 400 mg d3-d28 Orally |
| DRUG | azacitidine | 75 mg/m 2 /d subcutaneous injection or IV d1-d7 |
Timeline
- Start date
- 2024-08-05
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
- First posted
- 2024-04-26
- Last updated
- 2025-08-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06386302. Inclusion in this directory is not an endorsement.